Patterns of care for men with prostate cancer after failure of primary treatment

Cancer

Volumn 107, Issue 2, 2006, Pages 258-265

  Krupski, Tracey L ^a,d   Saigal, Christopher S ^b,c   Hanley, Janet ^c   Schonlau, Matthias ^c   Litwin, Mark S ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RAND CORPORATION   (United States)

^d Duke Health Raleigh Hospital   (United States)

Author keywords

Patterns of care; Prostate cancer; Recurrence; Secondary therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACADEMIC ACHIEVEMENT; ADULT; AGED; ALGORITHM; ARTICLE; BRACHYTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; DEMOGRAPHY; ETHNIC GROUP; GEOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CARE PLANNING; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; SOCIOECONOMICS; TREATMENT FAILURE; UNITED STATES;

AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; ETHNIC GROUPS; HUMANS; MALE; MIDDLE AGED; MINORITY GROUPS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 33745872582     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21981     Document Type: Article

References (27)

1. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94:981-990.
2. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. 1994;152(5 Pt 2):1850-1857.
3. Ragde H, Grado GL, Nadir BS. Brachytherapy for clinically localized prostate cancer: Thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone. Arch Esp Urol. 2001;54:739-747.
4. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-1597.
5. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 2002;95:281-286.
6. Valicenti RK, Gomelia LG, Perez CA. Radiation therapy after radical prostatectomy: A review of the issues and options. Semin Radiat Oncol. 2003;13:130-140.
7. Zimmerman RA, Culkin DJ. Clinical strategies in the management of biochemical recurrence after radical prostatectomy. Clin Prostate Cancer. 2003;2:160-166.
8. Hellerstedt BA, Pienta KJ. The truth is out there: An overall perspective on androgen deprivation. Urol Oncol. 2003;21:272-281.
9. Messing E. The timing of hormone therapy for men with asymptomatic advanced prostate cancer. Urol Oncol. 2003;21:245-254.
10. Patterson SG, Balducci L, Pow-Sang JM. Controversies surrounding androgen deprivation for prostate cancer. Cancer Control. 2002;9:315-325.
11. Grossfeld GD, Li YP, Carroll PR. Patterns of failure after primary local therapy for prostate cancer and rationale for secondary therapy. Urology 2002;60(3 Suppl 1):57-62; discussion 62-63.
12. Krupski TL, Kwan L, Litwin MS. Sociodemographic factors associated with postprostatectomy radiotherapy. Prostate Cancer Prostatic Dis. 2005;8:184-188.
13. Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology. 2004;64:1171-1176.
14. National Cancer Institute. Surveillance epidemiology and end results (SEER) Program Public-Use Data (1973-2001). Released 2003, based on November 2002 submission. Available at: www.seer.cancer.gov Accessed June 2004.
15. Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295-300.
16. Andriole GL. Adjuvant therapy for prostate cancer patients at high risk of recurrence following radical prostatectomy. Eur Urol. 1997;32 (Suppl 3):65-69.
17. Mosbacher MR, Schiff PB, Otoole KM, et al. Postprostatectomy salvage radiation therapy for prostate cancer: Impact of pathological and biochemical variables and prostate fossa biopsy. Cancer J. 2002;8:242-246.
18. Johnson CW, Anastasiadis AG, McKiernan JM, et al. Prognostic indicators for long term outcome following radical retropubic prostatectomy for prostate cancer involving the seminal vesicles. Urol Oncol. 2004;22:107-111.
19. Litwin MS, Saigal CS, Lubeck, Li YP, Henning JM, Carroll PR. Health-related quality of life in men with metastatic prostate cancer: The misleading effect of lead-time bias. BJU Int. 2003;91:9-13.
20. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1035-1041.
21. Horwitz EM, Vicini FA, Ziaja EL, et al., American Society of Therapeutic Radiology and Oncology. The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. Int J Radiat Oncol Biol Phys. 1998;41:267-272.
22. Ennis RD, Malyszko BK, Heitjan DF, Rubin MA, O'Toole KM, Schiff PB. Changes in biochemical disease-free survival rates as a result of adoption of the consensus conference definition in patients with clinically localized prostate cancer treated with external-beam radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41:511-517.
23. Thames H, Kuban D, Levy L, et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003;57:929-943.
24. Horwitz EM, Thames HD, Kuban DA, et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: A multi-institutional pooled analysis. J Urol. 2005;173:797-802.
25. Krupski TL, Kwan L, Afifi AA, Litwin MS. Geographic and Socioeconomic Variation in the Treatment of Prostate Cancer. J Clin Oncol. 2005;23:1-8.
26. Zeliadt SB, Penson DF, Albertsen PC, Concato J, Etzioni RD. Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. Cancer. 2003;98:496-503.
27. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095-101.